A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: An unusual presentation of a rare disease

Dong Chen, Veronika Bachanova, Rhett P. Ketterling, Kebede Begna, Curtis A. Hanson, David S. Viswanatha

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Rearrangement of the PDGFRA gene defines a distinct group of hematopoietic neoplasms that commonly present with persistent eosinophilia and are highly sensitive to low-dose imatinib mesylate treatment. Although rare cases of PDGFRA rearrangement-associated acute myeloid or lymphoblastic leukemia can occur, nonleukemic myeloid sarcoma has not been reported, and its sensitivity to imatinib treatment is unknown. Herein, we report a 31-year-old man with nonleukemic myeloid sarcoma and marked peripheral blood and bone marrow eosinophilia. Fluorescent in situ hybridization studies demonstrated that both bone marrow hematopoietic precursors and blasts of the myeloid sarcoma were positive for FIP1L1-PDGFRA rearrangement. The patient consequently received imatinib treatment at a dosage of 100 mg daily. After 3 weeks of therapy, his eosinophilia and myeloid sarcoma completely resolved, and at evaluation after 3 months he had attained bone marrow cytogenetic remission. To our knowledge, this is the first case of a nonleukemic myeloid sarcoma with the FIP1L1-PDGFRA rearrangement. Despite its aggressive clinical behavior attributed to myeloid sarcoma in general, the presence of PDGFRA rearrangement in this case conferred a high sensitivity to imatinib treatment and a favorable clinical outcome.

Original languageEnglish (US)
Pages (from-to)147-151
Number of pages5
JournalAmerican Journal of Surgical Pathology
Volume37
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Myeloid Sarcoma
Rare Diseases
Eosinophilia
Bone Marrow
Therapeutics
Gene Rearrangement
Hematologic Neoplasms
Fluorescence In Situ Hybridization
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Cytogenetics
Imatinib Mesylate

Keywords

  • eosinophilia
  • myeloid sarcoma
  • PDGFRA

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement : An unusual presentation of a rare disease. / Chen, Dong; Bachanova, Veronika; Ketterling, Rhett P.; Begna, Kebede; Hanson, Curtis A.; Viswanatha, David S.

In: American Journal of Surgical Pathology, Vol. 37, No. 1, 01.2013, p. 147-151.

Research output: Contribution to journalArticle

Chen, Dong ; Bachanova, Veronika ; Ketterling, Rhett P. ; Begna, Kebede ; Hanson, Curtis A. ; Viswanatha, David S. / A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement : An unusual presentation of a rare disease. In: American Journal of Surgical Pathology. 2013 ; Vol. 37, No. 1. pp. 147-151.
@article{3db5353d45f24ea1aebbeeab59886e5d,
title = "A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: An unusual presentation of a rare disease",
abstract = "Rearrangement of the PDGFRA gene defines a distinct group of hematopoietic neoplasms that commonly present with persistent eosinophilia and are highly sensitive to low-dose imatinib mesylate treatment. Although rare cases of PDGFRA rearrangement-associated acute myeloid or lymphoblastic leukemia can occur, nonleukemic myeloid sarcoma has not been reported, and its sensitivity to imatinib treatment is unknown. Herein, we report a 31-year-old man with nonleukemic myeloid sarcoma and marked peripheral blood and bone marrow eosinophilia. Fluorescent in situ hybridization studies demonstrated that both bone marrow hematopoietic precursors and blasts of the myeloid sarcoma were positive for FIP1L1-PDGFRA rearrangement. The patient consequently received imatinib treatment at a dosage of 100 mg daily. After 3 weeks of therapy, his eosinophilia and myeloid sarcoma completely resolved, and at evaluation after 3 months he had attained bone marrow cytogenetic remission. To our knowledge, this is the first case of a nonleukemic myeloid sarcoma with the FIP1L1-PDGFRA rearrangement. Despite its aggressive clinical behavior attributed to myeloid sarcoma in general, the presence of PDGFRA rearrangement in this case conferred a high sensitivity to imatinib treatment and a favorable clinical outcome.",
keywords = "eosinophilia, myeloid sarcoma, PDGFRA",
author = "Dong Chen and Veronika Bachanova and Ketterling, {Rhett P.} and Kebede Begna and Hanson, {Curtis A.} and Viswanatha, {David S.}",
year = "2013",
month = "1",
doi = "10.1097/PAS.0b013e31826df00b",
language = "English (US)",
volume = "37",
pages = "147--151",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement

T2 - An unusual presentation of a rare disease

AU - Chen, Dong

AU - Bachanova, Veronika

AU - Ketterling, Rhett P.

AU - Begna, Kebede

AU - Hanson, Curtis A.

AU - Viswanatha, David S.

PY - 2013/1

Y1 - 2013/1

N2 - Rearrangement of the PDGFRA gene defines a distinct group of hematopoietic neoplasms that commonly present with persistent eosinophilia and are highly sensitive to low-dose imatinib mesylate treatment. Although rare cases of PDGFRA rearrangement-associated acute myeloid or lymphoblastic leukemia can occur, nonleukemic myeloid sarcoma has not been reported, and its sensitivity to imatinib treatment is unknown. Herein, we report a 31-year-old man with nonleukemic myeloid sarcoma and marked peripheral blood and bone marrow eosinophilia. Fluorescent in situ hybridization studies demonstrated that both bone marrow hematopoietic precursors and blasts of the myeloid sarcoma were positive for FIP1L1-PDGFRA rearrangement. The patient consequently received imatinib treatment at a dosage of 100 mg daily. After 3 weeks of therapy, his eosinophilia and myeloid sarcoma completely resolved, and at evaluation after 3 months he had attained bone marrow cytogenetic remission. To our knowledge, this is the first case of a nonleukemic myeloid sarcoma with the FIP1L1-PDGFRA rearrangement. Despite its aggressive clinical behavior attributed to myeloid sarcoma in general, the presence of PDGFRA rearrangement in this case conferred a high sensitivity to imatinib treatment and a favorable clinical outcome.

AB - Rearrangement of the PDGFRA gene defines a distinct group of hematopoietic neoplasms that commonly present with persistent eosinophilia and are highly sensitive to low-dose imatinib mesylate treatment. Although rare cases of PDGFRA rearrangement-associated acute myeloid or lymphoblastic leukemia can occur, nonleukemic myeloid sarcoma has not been reported, and its sensitivity to imatinib treatment is unknown. Herein, we report a 31-year-old man with nonleukemic myeloid sarcoma and marked peripheral blood and bone marrow eosinophilia. Fluorescent in situ hybridization studies demonstrated that both bone marrow hematopoietic precursors and blasts of the myeloid sarcoma were positive for FIP1L1-PDGFRA rearrangement. The patient consequently received imatinib treatment at a dosage of 100 mg daily. After 3 weeks of therapy, his eosinophilia and myeloid sarcoma completely resolved, and at evaluation after 3 months he had attained bone marrow cytogenetic remission. To our knowledge, this is the first case of a nonleukemic myeloid sarcoma with the FIP1L1-PDGFRA rearrangement. Despite its aggressive clinical behavior attributed to myeloid sarcoma in general, the presence of PDGFRA rearrangement in this case conferred a high sensitivity to imatinib treatment and a favorable clinical outcome.

KW - eosinophilia

KW - myeloid sarcoma

KW - PDGFRA

UR - http://www.scopus.com/inward/record.url?scp=84871623818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871623818&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e31826df00b

DO - 10.1097/PAS.0b013e31826df00b

M3 - Article

C2 - 23232855

AN - SCOPUS:84871623818

VL - 37

SP - 147

EP - 151

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 1

ER -